EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients

Lin-Chun Chang, Michael T Yin iD, Gregory M Laird, Kristen D Ritter, Jayesh G Shah, Asim K Debnath iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Lin-Chun Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Virus Latency, bcl-X Protein, HIV-1, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Health, USA, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The persistence of latent HIV-1 proviruses in CD4+ T cells is a major obstacle to curing HIV. The “shock and kill” strategy involves reversing latency with latency-reversing agents (LRAs) and selectively inducing cell death in infected cells. However, current LRAs have shown limited efficacy in eliminating the ex vivo HIV reservoir and thus failed in clinical study. In this study, we repurposed PZ703b, a pro-apoptotic protein degrader initially developed for anti-leukemia therapy, to target HIV eradication. PZ703b induced the degradation of Bcl-2 and Bcl-xL, activating the non-canonical NF-kB pathway and caspases cascade, resulting in latency reversal and the selective apoptosis of infected cells. The treatment of ex vivo CD4+ T cells from ART-suppressed HIV-1 patients led to approximately a 50% reduction in the replication-competent reservoir. While this result does not reach the threshold required for a complete cure, it demonstrates the potential of a dual degrader of Bcl-2/Bcl-xL in reversing HIV latency and inducing selective cell death. Our study provides a proof-of-concept for using dual degraders of Bcl-2/Bcl-xL as a novel category of LRAs in therapeutic strategies aimed at reducing HIV reservoirs. This approach may pave the way for the further exploration of targeted interventions to eliminate the HIV-inducible reservoir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus Latencybcl-X ProteinHIV-1HIV InfectionsProto-Oncogene Proteins c-bcl-2Anti-HIV AgentsHumansCD4-Positive T-LymphocytesApoptosis

Stichwörter der Autor:innen

Bcl-2/Bcl-xLHIV latencyNF-kBnon-canonicalprotein degraderviral reservoirs

Substanzen

bcl-X ProteinProto-Oncogene Proteins c-bcl-2BCL2L1 protein, humanBCL2 protein, humanAnti-HIV Agents

Autor:innen und Institutionen

  • Laboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.
  • Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Accelevir Diagnostics, Baltimore, MD 21202, USA.

ORCID-Profile: Michael T Yin, Asim K Debnath

Förderung

  • NIAID NIH HHS
  • National Institute of Health, USA
  • NIH

Zitieren

APA

Chang, L. C., Yin, M. T., Laird, G. M., Ritter, K. D., Shah, J. G., & Debnath, A. K. (2025). A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062772

Vancouver

Chang LC, Yin MT, Laird GM, Ritter KD, Shah JG, Debnath AK. A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062772

BibTeX
@article{Chang2025,
  author = {Chang, Lin-Chun and Yin, Michael T and Laird, Gregory M and Ritter, Kristen D and Shah, Jayesh G and Debnath, Asim K},
  title = {A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062772}
}
Kostenlos starten →